Uni-Bio Science Group Limited Announces 2025 Annual Results
Record-Breaking Revenue of HK$586.2M and EPS Surged to HK$1.56 Cents
Dividends Distributed for Two Consecutive Years
Embarks on Innovation-Driven Transformation to Become a Global Pioneer in Regenerative Medicine
HONG KONG SAR - EQS Newswire - 27 March 2026 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the "Year").